| Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie | Frank Vinluan | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits | Frank Vinluan | 01/22/20 | New York |
| CEOs of Women’s Health Companies Fight to Open Investment Floodgates | Sarah de Crescenzo | 01/22/20 | San Diego |
| After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020 | Sarah de Crescenzo | 01/21/20 | San Diego |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| Mayo Clinic Joins $60M Financing for Biomedical Software Firm nference | Melissa Fassbender | 01/16/20 | Boston |
| Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D | Frank Vinluan | 01/15/20 | New York |
| Daré Bioscience Inks Deal With Bayer for Non-Hormonal Contraceptive | Sarah de Crescenzo | 01/14/20 | San Diego |
| Biogen Adds Another Neuro Drug to Pipeline in Deal With Pfizer | Melissa Fassbender | 01/13/20 | Boston |
| Roche Pays $40M to Use Amunix Pharma’s Half-Life Extension Tech | Melissa Fassbender | 01/13/20 | National |
| Neurocrine, in Second Epilepsy Deal, Pairs With Swiss Biotech Idorsia | Sarah de Crescenzo | 01/11/20 | San Diego |
| Eli Lilly Gets Skin in the Eczema Game With $1.1B Deal for Dermira | Frank Vinluan | 01/10/20 | Indiana |
| Biotech Roundup: Drug Pricing Promises, Bone Disease Data, IPO Plans & More | Sarah de Crescenzo | 01/10/20 | National |
| Biogen Teams Up With Startup CAMP4 to Scout for New Neuro Drugs | Frank Vinluan | 01/10/20 | Boston |
| UK Startups Double in Number Backed By Larger Scale Investments: Report | Melissa Fassbender | 01/09/20 | National |
| Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto | Sarah de Crescenzo | 01/07/20 | San Diego |
| Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex | Frank Vinluan | 01/06/20 | New York |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| No More Fish or Fruit: Intrexon Turns SynBio Focus to Human Health | Frank Vinluan | 01/02/20 | National |
| Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal | Sarah de Crescenzo | 12/23/19 | Boston |
| Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More | Sarah de Crescenzo | 12/20/19 | National |
| Takeda Pays Turnstone $120M to Start Alliance on Viral Cancer Therapies | Frank Vinluan | 12/19/19 | New York |
| Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s | Frank Vinluan | 12/17/19 | Boston |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal | Frank Vinluan | 12/12/19 | Boulder/Denver |
| Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer | Sarah de Crescenzo | 12/10/19 | San Diego |
| Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs | Frank Vinluan | 12/10/19 | New York |
| Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx | Sarah de Crescenzo | 12/09/19 | San Diego |
| Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule | Frank Vinluan | 12/09/19 | New York |
